Business Context and Reporting Period
Company: Utah Medical Products, Inc. (UTMD)
Filing Type: Form 10-Q (Unaudited)
Reporting Period: Quarter and nine months ended September 30, 2006
Business Overview: UTMD manufactures and markets specialty medical devices, including products for obstetrics, gynecology, neonatal care, and blood pressure monitoring. The company operates manufacturing facilities in Utah and Ireland.
Key Financial Metrics
| Metric (in thousands) | 3 Months Ended Sep 30, 2006 | 9 Months Ended Sep 30, 2006 |
|---|---|---|
| Net Sales | $7,001 | $21,398 |
| Gross Profit | $3,971 | $12,055 |
| Gross Margin % | 56.7% | 56.3% |
| Operating Income | $2,736 | $7,963 |
| Operating Margin % | 39.1% | 37.2% |
| Net Income | $2,003 | $6,098 |
| Diluted EPS | $0.50 | $1.51 |
| Cash Flow from Operations (9M) | $8,443 | |
| Cash & Investments (Sep 30, 2006) | $19,854 ($796 Cash + $19,058 Investments) | |
| Total Debt (Note Payable) | $4,989 | |
| Current Ratio | 8.6 |
Material Changes vs. Prior Period
- Revenue: Net sales were flat ($7.0M) for the third quarter compared to 2005, driven by a 12% increase in international sales offset by a 3% decline in domestic sales. For the nine-month period, sales increased 3% to $21.4M.
- Profitability: Net income increased 12% in Q3 and 8% in the nine-month period compared to the prior year. Operating margins expanded significantly (39.1% in Q3 vs. 29.1% in Q3 2005) primarily due to a $710 reduction in litigation expenses related to a resolved FDA dispute.
- Expenses: Selling, general, and administrative (SG&A) expenses decreased substantially year-over-year due to lower legal costs. However, the company began recognizing stock-based compensation expense ($108k for 9M 2006) following the adoption of SFAS 123R.
- Tax Rate: The effective tax rate increased to approximately 33-34% in 2006 compared to 20-27% in 2005, as the one-time tax benefit from the American Jobs Creation Act of 2004 was not available in the current period.
- Cash Flow: Operating cash flow for the nine months ended September 30, 2006, was $8.4M, a significant increase from $4.6M in the prior year, largely driven by a $1.9M increase in tax benefits from stock option exercises.
Guidance, Outlook, and Risks
- Outlook: Management expects full-year 2006 gross profit margins to be approximately 0.5 percentage points lower than 2005 due to inflationary pressures on raw materials (petroleum-based compounds) and labor costs. Operating expenses are projected to remain under 19% of sales for the full year.
- Capital Allocation: The company plans to utilize excess cash for selective acquisitions, continued share repurchases (7,132 shares repurchased in Q3), and dividends ($2.1M paid in 9M 2006).
- Debt: The company has a $4.99M note payable related to its Ireland subsidiary, incurred to repatriate foreign profits. Repayment is expected to take approximately four years from future Irish operations profits.
- Risks: Key risks include market acceptance of competitive products, regulatory approvals, reimbursement changes, and foreign currency fluctuations (Euro/USD). The company does not use hedging transactions for currency risk.
- Accounting Changes: The company adopted SFAS 123R for stock-based compensation in 2006. FIN 48 regarding uncertainty in income taxes will be adopted in Q1 2007, with the impact currently unknown.
Investor Verification Checklist
- Litigation Resolution: Verify the final status of the FDA lawsuit and confirm no new legal contingencies have arisen that could impact future SG&A expenses.
- Margin Sustainability: Assess the company's ability to pass on rising raw material and labor costs to customers given the inelastic nature of hospital pricing agreements.
- Debt Repayment Source: Confirm the cash flow generation of the Ireland subsidiary to ensure the $4.99M note payable can be serviced without impacting U.S. operations.
- Stock-Based Compensation: Review the pro-forma impact of SFAS 123R on future earnings, as the expense is expected to continue in 2006 and beyond.
- Share Repurchase Program: Monitor the pace of share buybacks and their impact on diluted share count and EPS growth.